Hong Kong · Delayed Price · Currency is HKD WuXi Biologics Statistics
Total Valuation
WuXi Biologics has a market cap or net worth of HKD 170.68 billion. The enterprise value is 167.04 billion.
| Market Cap | 170.68B |
| Enterprise Value | 167.04B |
Important Dates
The next estimated earnings date is Wednesday, November 19, 2025.
| Earnings Date | Nov 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
WuXi Biologics has 4.06 billion shares outstanding. The number of shares has decreased by -2.55% in one year.
| Current Share Class | 4.06B |
| Shares Outstanding | 4.06B |
| Shares Change (YoY) | -2.55% |
| Shares Change (QoQ) | -0.30% |
| Owned by Insiders (%) | 0.54% |
| Owned by Institutions (%) | 35.20% |
| Float | 3.54B |
Valuation Ratios
The trailing PE ratio is 38.78 and the forward PE ratio is 31.05. WuXi Biologics's PEG ratio is 1.63.
| PE Ratio | 38.78 |
| Forward PE | 31.05 |
| PS Ratio | 7.77 |
| PB Ratio | 3.17 |
| P/TBV Ratio | 3.62 |
| P/FCF Ratio | 88.54 |
| P/OCF Ratio | 27.22 |
| PEG Ratio | 1.63 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.91, with an EV/FCF ratio of 86.65.
| EV / Earnings | 36.33 |
| EV / Sales | 7.60 |
| EV / EBITDA | 21.91 |
| EV / EBIT | 27.77 |
| EV / FCF | 86.65 |
Financial Position
The company has a current ratio of 2.88, with a Debt / Equity ratio of 0.10.
| Current Ratio | 2.88 |
| Quick Ratio | 2.40 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.73 |
| Debt / FCF | 2.90 |
| Interest Coverage | 31.72 |
Financial Efficiency
Return on equity (ROE) is 10.50% and return on invested capital (ROIC) is 6.64%.
| Return on Equity (ROE) | 10.50% |
| Return on Assets (ROA) | 5.89% |
| Return on Invested Capital (ROIC) | 6.64% |
| Return on Capital Employed (ROCE) | 10.57% |
| Revenue Per Employee | 1.75M |
| Profits Per Employee | 366,331 |
| Employee Count | 12,575 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 6.36 |
Taxes
In the past 12 months, WuXi Biologics has paid 1.35 billion in taxes.
| Income Tax | 1.35B |
| Effective Tax Rate | 20.03% |
Stock Price Statistics
The stock price has increased by +95.80% in the last 52 weeks. The beta is 0.42, so WuXi Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | +95.80% |
| 50-Day Moving Average | 35.04 |
| 200-Day Moving Average | 25.96 |
| Relative Strength Index (RSI) | 67.81 |
| Average Volume (20 Days) | 43,129,112 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, WuXi Biologics had revenue of HKD 21.98 billion and earned 4.60 billion in profits. Earnings per share was 1.08.
| Revenue | 21.98B |
| Gross Profit | 9.37B |
| Operating Income | 6.02B |
| Pretax Income | 6.74B |
| Net Income | 4.60B |
| EBITDA | 7.46B |
| EBIT | 6.02B |
| Earnings Per Share (EPS) | 1.08 |
Balance Sheet
The company has 13.74 billion in cash and 5.60 billion in debt, giving a net cash position of 8.14 billion or 2.00 per share.
| Cash & Cash Equivalents | 13.74B |
| Total Debt | 5.60B |
| Net Cash | 8.14B |
| Net Cash Per Share | 2.00 |
| Equity (Book Value) | 53.76B |
| Book Value Per Share | 12.11 |
| Working Capital | 17.49B |
Cash Flow
In the last 12 months, operating cash flow was 6.27 billion and capital expenditures -4.34 billion, giving a free cash flow of 1.93 billion.
| Operating Cash Flow | 6.27B |
| Capital Expenditures | -4.34B |
| Free Cash Flow | 1.93B |
| FCF Per Share | 0.47 |
Margins
Gross margin is 42.65%, with operating and profit margins of 27.38% and 20.92%.
| Gross Margin | 42.65% |
| Operating Margin | 27.38% |
| Pretax Margin | 30.69% |
| Profit Margin | 20.92% |
| EBITDA Margin | 33.93% |
| EBIT Margin | 27.38% |
| FCF Margin | 8.77% |
Dividends & Yields
WuXi Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.55% |
| Shareholder Yield | n/a |
| Earnings Yield | 2.69% |
| FCF Yield | 1.13% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 16, 2020. It was a forward split with a ratio of 3.
| Last Split Date | Nov 16, 2020 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
WuXi Biologics has an Altman Z-Score of 5.11 and a Piotroski F-Score of 7.
| Altman Z-Score | 5.11 |
| Piotroski F-Score | 7 |